



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution form 1449/APTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet	1	of	3	Application Number	10/552,595
				Filing Date	October 7, 2005
				First Named Inventor	Morand <i>et al.</i>
				Group Art Unit	1614
				Examiner	Unassigned
				Attorney Docket Number	11982.105003 BDW004 US

4010836 1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear
	AA	4,616,025	A	Ezer <i>et al.</i>	10-07-1986	
	AB	6,235,910	A	Beller <i>et al.</i>	05-22-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document Office ² Number	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AC	DE 19940211	A1	DeGussa-Hüls AG	03-23-2000	
	AD	GB 2,910,827	A	Eli Lilly & Co.	07-04-1979	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
(Y.C.)	AE	BACHER, M., <i>et al.</i> , "An essential regulatory role for macrophage migration inhibitory factor in T-cell activation," <i>Proc. Natl. Acad. Sci. USA</i> , 93(15):7849-7854 (July 23, 1996).	
	AF	BOZZA, M., <i>et al.</i> , "Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis," <i>J. Exp. Med.</i> , 189(2):341-346 (January 18, 1999).	
	AG	BUCALA, R., "MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response," <i>FASEB J.</i> , 10(14):1607-1613 (December 1996).	
	AH	CALANDRA, T., <i>et al.</i> , "MIF as a glucocorticoid-induced modulator of cytokine production," <i>Nature</i> , 377(6544):68-71 (September 7, 1995).	
	AI	DAVID, J.R., "Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction," <i>Proc. Natl. Acad. Sci. USA</i> , 56(1):72-77 (July 1966).	
	AJ	DONNELLY, S.C., <i>et al.</i> , "Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome," <i>Nat. Med.</i> , 3(3):320-323 (March 1997).	
	AK	JÜTTNER, S., <i>et al.</i> , "Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha," <i>J. Immunol.</i> , 161(5):2383-2390 (September 1, 1998).	
↓ (Y.C.)	AL	KARIMI, B., <i>et al.</i> , "Efficient and chemoselective conversion of carbonyl compounds to 1,3-dioxanes catalyzed with N-bromosuccinimide under almost neutral reaction conditions," <i>Org. Lett.</i> , 1(11):1737-1739 (1999).	
(Y.C.)	AM	LACEY, D., <i>et al.</i> , "Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor," <i>Arthritis Rheum.</i> , 48(1):103-109 (January 2003).	

Examiner Signature	(Yong Chui)	Date Considered	02/13/2008
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Please place a plus sign (+) inside this box



FTO/5B4084 (08-00)

Approved for use through 10/31/2002. OMB 0651-0001
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submit this form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known	
Application Number	10/552,595
Filing Date	October 7, 2005
First Named Inventor	Morand et al.
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	11982.105003 BDW004 US

4010836 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
Y.C.J.	BA	LEECH, M., et al., "Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of pro-inflammatory function and regulation by glucocorticoids," <i>Arthritis & Rheumatism</i> , 42(8):1604-1608 (August 1999)	
	BB	LEECH, M., et al., "Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant arthritis," <i>Arthritis & Rheumatism</i> , 43(4):827-833 (April 2000).	
	BC	LEECH, M., et al., "Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis," <i>Arthritis Rheum.</i> , 48(7):1881-1889 (July 2003)	
	BD	LIANG, X., et al., "Solution-phase combinatorial synthesis using multicomponent Grignard reagents," <i>J. Chem. Soc., Perkin Trans. I</i> , 2002:503-508 (2002)	
	BE	MIMURA, T., et al., "Platelet anti-aggregant activity of 2,2-dimethylthiazolidine hydrochloride and 2-(4-hydroxy-3-methoxyphenyl)thiazolidine," <i>Chem. Pharm. Bull.</i> , 36(3):1110-1116 (1988).	
	BF	MITCHELL, R.A., et al., "Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action," <i>J. Biol. Chem.</i> , 274(25):18100-18106 (June 18, 1999)	
	BG	MORAND, E.F., et al., "Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis," <i>Arthritis & Rheumatism</i> , 48(2):291-299 (February 2003).	
	BH	PERRIN, C.L., et al., "Stereochemical control in addition of nucleophiles to an amidinium ion," <i>J. Am. Chem. Soc.</i> , 123:4451-4458 (2001).	
	BI	QUALLICH, G.J., et al., "Synthesis of 1,2,3,4-tetrahydroisoquinolines containing electron-withdrawing groups," <i>J. Org. Chem.</i> , 63(12):4116-4119 (1998).	
	BJ	ROBBE, Y., et al., "Radioprotection chimique comparée de diverses structures hétéro-cycliques pentagonales à deux hétéroatomes," <i>Eur. J. Med. Chem. – Chim. Ther.</i> , 17(3):235-243 (1982).	
	BK	SABROE, I., et al., "Asthma and MIF: innately Th1 and Th2," <i>Clin. Exp. Allergy</i> , 30(9):1194-1196 (September 2000).	
	BL	SAMAJDAR, S., et al., "A new molecular iodine-catalyzed thioetherization of carbonyl compounds: selectivity and scope," <i>Tetrahedron Lett.</i> , 42:4425-4427 (2001).	
	BM	SAMPEY, A.V., et al., "Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes," <i>Mediators Inflamm.</i> , 9(3-4):125-132 (2000).	
Y.C.J.	BN	SAMPEY, A.V., et al., "Regulation of synovocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor," <i>Arthritis Rheum.</i> , 44(6):1273-1280 (June 2001).	

Examiner Signature	/Yong Chu/	Date Considered	02/13/2008
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Please print a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0001
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				Complete If Known Application Number 10/552,595 Filing Date October 7, 2005 First Named Inventor Morand <i>et al.</i> Group Art Unit 1614 Examiner Name Unassigned Attorney Docket Number 11982.105003 BDW004 US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
Sheet	3	of	3		

4010836 1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
Y.C.J.	CA	SANTOS, L., <i>et al.</i> , "Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids," <i>Clin. Exp. Immunol.</i> , 123(2):309-314 (February 2001).			
Y.C.J.	CB	SANTOS, L.L., <i>et al.</i> , "Suppression of adjuvant arthritis and synovial macrophage inducible nitric oxide by N-iminoethyl-L-ornithine, a nitric oxide synthase inhibitor," <i>Inflammation</i> , 21(3):299-311 (June 1997).			
Y.C.J.	CC	SPYCHALA, J., "4-(Cyclic amidino)phenols- preparation and use in a diamidine synthesis," <i>Synthetic Communications</i> , 30(6):1083-1094 (2000).			
Y.C.J.	CD	SRIKRISHNA, A., <i>et al.</i> , "A mild and simple procedure for the reductive cleavage of acetals and ketals," <i>Tetrahedron</i> , 31(11):3339-3344 (1995).			
Y.C.J.	CE	SUMIYA, F., <i>et al.</i> , "Conjugated-triene intermediates in the Sommelet-Hauser rearrangement of cyclic 1-methyl-2-phenylammonium 1-methylides," <i>Chem. Pharm. Bull.</i> , 39(1):36-40 (January 1991).			
Y.C.J.	CF	WEISER, W.Y., <i>et al.</i> , "Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor," <i>Proc. Natl. Acad. Sci. USA</i> , 86(19):7522-7526 (October 1989).			
Y.C.J.	CG	WENIS, E., <i>et al.</i> , "The synthesis of p-aminosalicylic acid hydrochloride," <i>J. Am. Pharm. Assoc.</i> , 38:9-11 (1949) (Abstract only).			
Y.C.J.	CH	WILK, I.J., <i>et al.</i> , "The action of lithium aluminum hydride on 3-methyl-5-phenylhydantoin and 5-phenylhydantoin," <i>J. Org. Chem.</i> , 15:1020-1022 (1950).			
	CI	YORDANOVA, K., <i>et al.</i> , "Eine neue Methode zur Darstellung von 2,4-disubstituierten Morpholinen," <i>Chem. Ber.</i> , 115(7):2635-1642 (1982).			
Y.C.J.	CJ	YUS, M., <i>et al.</i> , "A new and direct synthesis of 2-substituted pyrrolidines," <i>J. Org. Chem.</i> , 66(18):6207-6208 (2001).			

The crossed-out reference is not considered, because no English translation is provided.

Examiner Signature	/Yong Chau/	Date Considered	02/13/2008
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.